- All
- Product Management
- News
- Introduction
- Enterprise outlets
- FAQ
- Enterprise Video
- Enterprise Atlas
Chuangyuan Biotechnology has obtained another national invention patent authorization related to its proprietary strains research.
On November 12, 2024, Tianjin Chuangyuan Biotechnology Co., Ltd. obtained an invention patent certificate issued by the National Intellectual Property Administration for its independently developed and filed patent titled "A Bifidobacterium animalis subsp. lactis for Reducing A β 42 Deposition and Its Application" (Patent No: ZL 202411230717.5).

The invention provides a Bifidobacterium animalis subsp. lactis for reducing A β 42 deposition and its application, relating to the field of microbiology. The name of the Bifidobacterium animalis subsp. lactis is IOB-L07, classified asBifidobacterium animalis subsp. lactis, which was preserved on December 23, 2021, at the General Microbial Culture Collection Center of the China Microbial Culture Collection Management Committee, abbreviated as CGMCC, with the preservation number CGMCC No. 24185.According to animal experiments, this strainreduces the content of A β 42 in the cerebral cortex and hippocampus, clears A β amyloid plaques, improves communication between neurons, reduces brain neuroinflammation, protects nerve cells, helps restore cognitive function, and improves gut microbiota imbalance caused by Alzheimer's disease.

Related News